Your browser doesn't support javascript.
loading
Secondary pituitary hormonal dysfunction patterns: tumor size and subtype matter.
Almistehi, Wael M; Vaninetti, Nadine; Mustafa, Syed; Hebb, Andrea L O; Zwicker, Deborah; Doucette, Steve; Alqahtani, Saif; Clarke, David B; Imran, Syed Ali.
Afiliação
  • Almistehi WM; Division of Endocrinology and Metabolism, Dalhousie University, Halifax, NS, Canada.
  • Vaninetti N; Division of Endocrinology and Metabolism, Dalhousie University, Halifax, NS, Canada.
  • Mustafa S; Division of Endocrinology and Metabolism, Dalhousie University, Halifax, NS, Canada.
  • Hebb ALO; Division of Neurosurgery, Dalhousie University, Halifax, NS, Canada.
  • Zwicker D; Division of Endocrinology and Metabolism, Dalhousie University, Halifax, NS, Canada.
  • Doucette S; Research Methods Unit, Nova Scotia Health Authority, Halifax, NS, Canada.
  • Alqahtani S; Division of Endocrinology and Metabolism, Dalhousie University, Halifax, NS, Canada.
  • Clarke DB; Division of Endocrinology and Metabolism, Dalhousie University, Halifax, NS, Canada.
  • Imran SA; Division of Neurosurgery, Dalhousie University, Halifax, NS, Canada.
Pituitary ; 23(6): 622-629, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32715387
ABSTRACT

PURPOSE:

Patients with sellar masses (SM) frequently have secondary hormonal deficiency (SHD) at initial presentation. While larger SM are more likely to present with SHD, it is unclear whether SHD at presentation is influenced by the type of SM.

METHODS:

We conducted a retrospective analysis of patients with SM prospectively enrolled in our comprehensive provincial neuropituitary registry between November 2005 and December 2018. SM were subdivided based on size < 1 cm, 1-1.9 cm, 2-2.9 cm, and > 3 cm.

RESULTS:

A total of 914 patients met the inclusion criteria, including 346 nonfunctioning adenomas (NFA), 261 prolactinomas (PRLoma), 51 growth hormone adenomas, 36 adrenocorticotropic adenomas, 93 Rathke's cleft cysts, 70 craniopharyngiomas and 57 meningiomas. The overall rate of SHD at presentation was highest in PRLoma (62.8%) and craniopharyngiomas (64.3%) and lowest in meningiomas (14%). While larger SM were significantly more likely to have SHD, the rate of SHD within each group was significantly different despite similar size (p < 0.001). Of the two largest groups of SM (NFA and PRLoma), NFA had significantly higher odds ratio (3.34, CI 1.89-5.89) of having multiple SHDs when compare with PRLoma, even when corrected for age, gender and size of tumor (p < 0.001).

CONCLUSION:

Our study shows that the rate and distribution of SHD in SM vary dependent upon the size of the tumor and specific pathology; in particular, NFA are more likely to present with multiple SHDs. Our data will help clinicians in determining adequate hormonal testing strategy for different SM.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prolactinoma / Adenoma Tipo de estudo: Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Pituitary Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prolactinoma / Adenoma Tipo de estudo: Observational_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Pituitary Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá